VITEXIN AS A CHRONOTHERAPEUTIC AGENT FOR CIRCADIAN-ASSOCIATED COLONIC COMPLICATIONS IN DIABETES: A REVIEW

Abstract

Diabetes mellitus is increasingly recognized as a disorder that extends beyond glycemic dysregulation to encompass significant colonic pathology, characterized by epithelial injury, barrier dysfunction, and microbial dysbiosis mediated by hyperglycemia-induced oxidative and inflammatory stress. Concurrently, circadian clock genes—most notably Bmal1— have emerged as critical regulators of colonic epithelial renewal, tight-junction integrity, and mucosal immune homeostasis, with circadian disruption shown to independently exacerbate colonic injury. Vitexin, a naturally occurring C-glycosylated flavone, exhibits well-documented antidiabetic, anti-inflammatory, anti-apoptotic, and gut-microbiota-modulating properties that converge mechanistically on several molecular nodes governed by BMAL1, raising the hypothesis of an unexplored circadian dimension to its pharmacological action. Vitexin was found to inhibit intestinal α-glucosidase activity, attenuate NF-κB-mediated inflammatory signaling and adhesion-molecule expression, activate Nrf2-dependent antioxidant defenses, preserve mitochondrial dynamics, protect intestinal barrier integrity in experimental colitis models, and favorably modulate gut microbial composition. These effects operate through Nrf2, NF-κB, and AMPK/SIRT1 signaling axes, each independently established as reciprocal regulators of the CLOCK–BMAL1 transcription–translation feedback loop. Notably, a structurally analogous polyphenol has been demonstrated to restore BMAL1 rhythmicity in metabolically stressed hepatocytes, lending indirect support to the plausibility of a similar effect for vitexin. However, no published study to date has directly examined vitexin's influence on BMAL1, CLOCK, PER, or CRY expression, nor assessed whether its protective effects are time-of-administration dependent. Vitexin represents a mechanistically plausible, though experimentally unverified, chronotherapeutic candidate for circadian-associated diabetic colonic disease.